Literature DB >> 23904233

CD30-positive malignant lymphomas: time for a change of management?

Andreas Engert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23904233      PMCID： PMC3729895          DOI： 10.3324/haematol.2013.091561

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  23 in total

1.  Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.

Authors:  Kevin J Hamblett; Peter D Senter; Dana F Chace; Michael M C Sun; Joel Lenox; Charles G Cerveny; Kim M Kissler; Starr X Bernhardt; Anastasia K Kopcha; Roger F Zabinski; Damon L Meyer; Joseph A Francisco
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

Review 2.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy.

Authors:  B Falini; S Pileri; G Pizzolo; H Dürkop; L Flenghi; F Stirpe; M F Martelli; H Stein
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

3.  Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.

Authors:  U Schwab; H Stein; J Gerdes; H Lemke; H Kirchner; M Schaadt; V Diehl
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

4.  Recurrent Hodgkin's disease after bone marrow transplantation.

Authors:  I Shahab; J P Greer; T A Beeker; S N Wolff; R D Collins; J B Cousar
Journal:  Am J Clin Pathol       Date:  1997-01       Impact factor: 2.493

5.  Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.

Authors:  A Engert; F Burrows; W Jung; P L Tazzari; H Stein; M Pfreundschuh; V Diehl; P Thorpe
Journal:  Cancer Res       Date:  1990-01-01       Impact factor: 12.701

Review 6.  The diagnostic significance of the CD30 (Ki-1) antigen.

Authors:  G Pallesen
Journal:  Histopathology       Date:  1990-04       Impact factor: 5.087

7.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Authors:  Joseph A Francisco; Charles G Cerveny; Damon L Meyer; Bruce J Mixan; Kerry Klussman; Dana F Chace; Starr X Rejniak; Kristine A Gordon; Ron DeBlanc; Brian E Toki; Che-Leung Law; Svetlana O Doronina; Clay B Siegall; Peter D Senter; Alan F Wahl
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

8.  Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

Authors:  Roland Schnell; Markus Dietlein; Jan Oliver Staak; Peter Borchmann; Klaus Schomaecker; Thomas Fischer; Wolfgang Eschner; Hinrich Hansen; Franck Morschhauser; Harald Schicha; Volker Diehl; Andrew Raubitschek; Andreas Engert
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

9.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

10.  Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population.

Authors:  H Stein; J Gerdes; U Schwab; H Lemke; D Y Mason; A Ziegler; W Schienle; V Diehl
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396
View more
  2 in total

Review 1.  Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.

Authors:  Christopher G England; Lixin Rui; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-14       Impact factor: 9.236

Review 2.  Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.